title: Risk of cardiovascular disease in kidney donors as a chronic kidney             disease cohort.
abstract: Kidney donors are a chronic kidney disease (CKD) cohort virtually guaranteed to have a low risk of CKD progression, as they are screened for CKD risk factors beforehand. However, there has been no evidence of cardiovascular disease (CVD), which is an outcome of CKD, for these donors. In this study, the conditions of CKD in kidney donors were investigated and the risk of CVD was estimated using nephrectomy patients, who are thought to have a crude risk of CKD progression, as a model. In 86 kidney donors, estimated glomerular filtration rates (eGFR) were measured, and they were classified according to the CKD stage. Plasma brain natriuretic peptide (BNP) concentrations and urinary albumin (mg/g Cre) levels were also measured as markers for cardiovascular evaluation. A total of 200 nephrectomy patients were similarly classified according to the CKD stage. A multivariate regression analysis was carried out to evaluate the risk factors of CVD. Among the kidney donors, 4.9% were CKD stage 1, 24.6% stage 2 and 70.5% stage 3. Among the nephrectomy patients, 20.5% were CKD stage 2, 66.6% stage 3, 9.5% stage 4 and 3.4% stage 5. Plasma BNP concentrations of the donors were significantly higher compared to those of healthy volunteers (24.5±24.9 vs. 8.6±7.6 pg/ml, p<0.0001). In addition, approximately 16% of the donors had microalbuminuria and 4% had overt proteinuria. The prevalence of new-onset CVD was 2.3% for the donors and 10% for the nephrectomy patients (p=0.0281). By logistic regression analysis of the nephrectomy patients, proteinuria, age and hypertension were significantly independent risk factors for new-onset CVD. Our findings suggest that the risks of CVD may be increased in kidney donors. In our analysis of new-onset CVD in nephrectomy patients, proteinuria, age and hypertension were significantly related factors. This suggests that in the follow-up of kidney donors, those who present these conditions from before or during follow-up should be carefully monitored.
authors: Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan. spxd48k9@aria.ocn.ne.jp
authors: Toshihide
authors: T
authors: Naganuma
authors: Yoshiaki
authors: Y
authors: Takemoto
authors: Ootoshi
authors: O
authors: Taiyou
authors: Tachibana
authors: T
authors: Hirokazu
authors: Murao
authors: M
authors: Masaki
authors: Satoshi
authors: S
authors: Maeda
authors: Tatsuya
authors: T
authors: Nakatani
mesh_terms: D000328:Adult; D000367:Age Factors; D000419:Albuminuria / Q000150:complications / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology*; D002908:Chronic Disease; D015331:Cohort Studies; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications; D007674:Kidney Diseases / Q000150:complications* / Q000175:diagnosis; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009392:Nephrectomy; D016017:Odds Ratio; D015995:Prevalence; D011507:Proteinuria / Q000150:complications; D012307:Risk Factors; D012709:Serum Albumin / Q000032:analysis; D014019:Tissue Donors / Q000706:statistics & numerical data
chemical_list: D012709:Serum Albumin; D020097:Natriuretic Peptide, Brain